RESUMO
Background. Congenital absence of the portal vein (CAPV) is an extremely rare malformation that is caused by aberrant venous development during embryogenesis and is usually associated with congenital portosystemic shunts (CPSS). This hemodynamic allows mesenteric blood to bypass the liver metabolism and causes an imbalance between vasodilators and vasoconstrictors in the pulmonary circulation, which, again, might lead to the development of secondary portopulmonary hypertension (PoPH). Establishing the exact morphology of the splanchnic venous system is important when evaluating possible therapeutic options (differentiating type I and II CAPV), because some variants enable the closure of the shunt, and this represents a potential cure for pulmonary arterial hypertension (PAH). Once PoPH is diagnosed, complex care in a specialized expert centre is necessary. If possible, CPSS closure is recommended. For long-term successful patient management, specific targeted PAH therapy administration is crucial. Significant morbidity and mortality in these patients may result not only from PAH itself but also due to specific PoPH complications, such as compression of the left main coronary artery by pulmonary artery aneurysm. Case Report. We report on two patients with PoPH due to CAPV and CPSS (without any liver disease) who presented as severe PAH and who, before admission to our expert centre, were misdiagnosed as idiopathic PAH. The case reports also represent our experience with respect to the long-term follow-up and PAH-specific medical treatment of these patients, as well as the possible (even fatal) complications of these rare and complex patients.
Assuntos
Hipertensão Portal , Hipertensão Pulmonar , Hipertensão Arterial Pulmonar , Malformações Vasculares , Humanos , Veia Porta , Hipertensão Portal/complicações , Vasodilatadores , Vasoconstritores/uso terapêuticoRESUMO
Background and Objectives: Chronic thromboembolic pulmonary hypertension (CTEPH) is a chronic progressive disease, resulting from persistent arterial obstruction combined with small-vessel remodeling. Central and peripheral CTEPH are distinguished, according to the dominant lesion's location. This is important for surgical or percutaneous interventional assessment or for medical treatment. Material and Methods: Eighty-one patients (51 male/30 female) with confirmed CTEPH were analyzed, while the CENTRAL type included 51 patients (63%) and the PERIPHERAL type 30 patients (37%). Results: A significant difference in CENTRAL type vs. PERIPHERAL type was determined in gender (male 72.5% vs. 46.7%; p = 0.0198). No difference was found in age, functional status, or echocardiographic parameters. Invasive hemodynamic parameters showed a significant difference in mean pulmonary arterial pressure (46 vs. 58 mmHg; p = 0.0002), transpulmonary gradient (34 vs. 47 mmHg; p = 0.0005), and cardiac index (2.04 vs. 2.5 L.min.m2; p = 0.02) but not in pulmonary vascular resistance. Risk factors showed a significant difference only in acute pulmonary embolism (93.8% vs. 60%; p = 0.0002) and malignancy (2% vs. 13.3%; p = 0.0426). Conclusions: Our study showed hemodynamic differences between CENTRAL type vs. PERIPHERAL type CTEPH with a worse hemodynamic picture in CENTRAL form. This may indicate a different pathophysiological response and/or possible additional influences contributing especially to the peripheral pulmonary bed affection.
Assuntos
Hipertensão Pulmonar , Embolia Pulmonar , Humanos , Masculino , Feminino , Hipertensão Pulmonar/complicações , Hipertensão Pulmonar/tratamento farmacológico , Embolia Pulmonar/complicações , Hemodinâmica , Pulmão , Resistência Vascular , Doença CrônicaRESUMO
Right ventricle (RV) is frequently neglected in comparison with left ventricle in many aspects - pathogenetic, diagnostic or therapy. In contrast with this, right chamber is pathologically an active part in severe pulmonary arterial hypertension (PAH) associated with congenital heart defects and also importantly influences its course and prognosis. Life expectancy and quality of life do not depend on pulmonary pressure. Inversely, function and status of RV is determining. Eisenmenger´s syndrome presents an extreme severe form of PAH. Unique adaptation ability of different and specific RV causes better symptomatic image of patients with Eisenmenger´s syndrome among all patients with PAH.
Assuntos
Complexo de Eisenmenger/diagnóstico , Hipertensão Pulmonar/diagnóstico , Humanos , Prognóstico , Índice de Gravidade de DoençaRESUMO
Background: Pulmonary artery dilatation is described mostly in association with pulmonary hypertension. Patients/Methods: Study analysis: 60 patients with pulmonary arterial hypertension in congenital heart disease (PAH-CHD); 64 with repaired tetralogy of Fallot/pulmonary regurgitation (rTOF/PR); and 80 healthy (NORMAL). Measured were: main pulmonary artery (MPA) diameter and MPA/ascending aorta (Ao asc) ratio, by echocardiography (ECHO) and computer tomography or magnetic resonance imaging (CT/MRI). Results: In MPA diameter, significant differences between PAH-CHD, rTOF/PR, and NORMAL were found (median): 37 vs. 27 vs. 21 mm (p < 0.0001). In MPA/Ao asc ratio, there was a difference between PAH-CHD and NORMAL (median): 1.3 vs. 0.8 (p < 0.0001), but not between rTOF/PR and NORMAL: 0.74 vs. 0.8 (p = 0.3). Significant MPA dilatation (>40 mm) was present: in PAH-CHD, 35% (ECHO) and 76.9% (CT/MRI) of patients, while in rTOF/PR, 3.1% (ECHO) and 7.8% (CT/MRI). Severe MPA dilatation (>50 mm) occurred only in PAH-CHD: 16.7% (ECHO) and 31.4% (CT/MRI), while not in rTOF/PR. There was a significant correlation between ECHO and CT/MRI measurements, but ECHO was underestimated in all parameters. Conclusions: MPA dilatation due to pressure overload is more frequent and more severe; volume overload also leads to MPA dilatation but is less severe. The MPA/Ao asc ratio is not reliable for MPA dilatation estimation in rTOF/PR.
RESUMO
OBJECTIVES: To determine the long-term and transplantation-free survival of all patients after atrial correction of transposition of the great arteries (TGA) in the Czech and Slovak republics, including its preoperative and perioperative determinants. METHODS: Retrospective analysis of all 454 consecutive patients after atrial correction of TGA was performed. Of these, 126 (27.8%) were female, median age at operation was 7.4 months (Q1 5.3; Q3 13.3) and 164 (36.1%) underwent the Mustard procedure. The relationships between age, weight, the complexity of TGA, operative technique, additional surgical procedures, immediate postoperative presence of tricuspid regurgitation and revision procedures during follow-up to major composite outcome, as such defined as long-term and transplantation-free survival, were tested. RESULTS: Early 30-day mortality did not differ between the Mustard (9.76%) and Senning (8.97%) cohorts (p=0.866). The long-term and transplantation-free survival, which differed between the Mustard and Senning cohorts in favour of the Senning procedure (HR 0.43; 95% CI 0.21 to 0.87), was shorter in complex TGA (HR 2.4; 95% CI 1.59 to 3.78) and in complex surgical interventions (HR 3.51; 95% CI 2.31 to 5.56). The immediate presence of at least moderate tricuspid regurgitation after correction was associated with a shorter long-term and transplantation-free survival in the univariate but not in the multivariable model. CONCLUSIONS: The lower long-term survival of patients after an atrial switch operation of TGA in the Czech and Slovak republics is associated with greater complexity of TGA, complex surgical interventions and application of the the Mustard operative procedure.
Assuntos
Transposição das Grandes Artérias , Transposição dos Grandes Vasos , Insuficiência da Valva Tricúspide , Humanos , Feminino , Lactente , Masculino , Insuficiência da Valva Tricúspide/cirurgia , Estudos Retrospectivos , Transposição das Grandes Artérias/efeitos adversos , Artérias , Seguimentos , Resultado do TratamentoRESUMO
OBJECTIVES: Asphyxia of the newborn has a varied etiology. Clinical consequences have a broad spectrum of presentations. Arteriovenous malformation associated with an aneurysm of the Galen vein can be the cause of focal ischemic changes in the nervous parenchyma. RESULTS: The authors report a case of a term newborn (birth weight 4, 000 grams, Apgar score 7/9). Physical investigation confirmed the presence of a continuous murmur in the area of the anterior fontanelle. Ultrasonic investigation of the brain detected a huge arteriovenous malformation of the Galen vein. Ultrasonic investigation of the heart excluded structural anomaly, but confirmed a huge retrograde flow in the aorta descendens, opened ductus arterious with suspected formation of coarctation of the aorta and dilatation of the vena cava superior. CONCLUSION: Congenital anomaly of the Galen vein has a negative influence on prenatal and postnatal development of the brain of a newborn. In the case of our patient, it led to rapid severe asphyxiated changes of the brain parenchyma. Diagnosis and management were established, yet endovascular therapy was not indicated in the early neonatal period.
Assuntos
Sistema Cardiovascular/fisiopatologia , Veias Cerebrais/anormalidades , Malformações Arteriovenosas Intracranianas/fisiopatologia , Encéfalo/crescimento & desenvolvimento , Sistema Cardiovascular/diagnóstico por imagem , Veias Cerebrais/diagnóstico por imagem , Veias Cerebrais/fisiologia , Ecoencefalografia , Humanos , Recém-Nascido , Malformações Arteriovenosas Intracranianas/diagnóstico , Malformações Arteriovenosas Intracranianas/diagnóstico por imagemRESUMO
OBJECTIVE: To assess the efficacy and safety of subcutaneous treprostinil in adult patients with congenital heart disease (CHD)-associated pulmonary arterial hypertension (PAH) after 12 months of treatment. METHODS: Consecutive adult patients with CHD-PAH received subcutaneous treprostinil to maximum tolerated doses in an observational study. RESULTS: Advanced CHD-PAH patients with WHO class III or IV disease (n=32, age 40±10 years, 20 females) received treprostinil for suboptimal response to bosentan (n=12), WHO functional class IV disease (FC, n=7) or prior to bosentan approval (n=13). In the multivariate mixed model, mean increase in 6 min walk distance (6-MWD) from baseline to 12 months was 114 m (76; 152) (P<0.001). WHO FC improved significantly (P=0.001) and B-type brain natriuretic peptide decreased from 1259 (375; 2368) pg/mL to 380 (144; 1468) pg/mL (P=0.02). In those 14 patients who had haemodynamic data before and after initiation of treprostinil, pulmonary vascular resistance decreased significantly (from 18.4±11.1 to 12.6±7.9 Wood units, P=0.003). The most common adverse events were infusion-site erythema and pain. One patient stopped treatment because of intolerable infusion-site pain after 8 months of treatment. No other major treatment-related complications were observed. Five patients died during early follow-up, having experienced a decrease in their 6-MWD prior. CONCLUSIONS: Subcutaneous treprostinil therapy is generally safe and effective for at least 12 months and may be used in CHD-related PAH class III and IV.
Assuntos
Anti-Hipertensivos/uso terapêutico , Epoprostenol/análogos & derivados , Cardiopatias Congênitas/complicações , Hipertensão Pulmonar/tratamento farmacológico , Bombas de Infusão , Adulto , Estudos de Coortes , Epoprostenol/uso terapêutico , Feminino , Humanos , Hipertensão Pulmonar/classificação , Hipertensão Pulmonar/etiologia , Infusões Subcutâneas , Masculino , Peptídeo Natriurético Encefálico/sangue , Oxigênio/sangue , Resistência Vascular , Teste de CaminhadaRESUMO
Patients with severe pulmonary arterial hypertension suffer from life-threatening thrombotic and bleeding complications. The aim of this study was to compare selected platelet, endothelial, and coagulation parameters in healthy volunteers and patients with severe pulmonary arterial hypertension because of congenital heart defects. The study included healthy volunteers (nâ=â50) and patients with cyanotic congenital heart defects classified as Eisenmenger syndrome (nâ=â41). We investigated platelet count, mean platelet volume, and platelet aggregation - spontaneous and induced by various concentrations of five agonists. Von Willebrand factor (vWF), fibrinogen, factor VIII and XII, plasminogen activator inhibitor, antithrombin, D-dimer, and antiphospholipid antibodies were also investigated. We found a decreased platelet count [190 (147-225) vs. 248 (205-295) 10âl, Pâ<â0.0001], higher mean platelet volume [10.9 (10.1-12.0) vs. 10.2 (9.4-10.4)âfl, Pâ<â0.0001], and significantly decreased platelet aggregation (induced by five agonists, in various concentrations) in patients with Eisenmenger syndrome compared with controls. These changes were accompanied by an increase of plasma vWF antigen [141.6 (108.9-179.1) vs. 117.4 (9.2-140.7)âIU/dl, Pâ=â0.022] and serum anti-ß2-glycoprotein [2.07 (0.71-3.41) vs. 0.47 (0.18-0.99)âU/ml, Pâ<â0.0001]. Eisenmenger syndrome is accompanied by platelet abnormalities. Thrombocytopenia with increased platelet size is probably due to a higher platelet turnover associated with platelet activation. Impaired platelet aggregation can reflect specific platelet behaviour in patients with Eisenmenger syndrome. These changes can be related both to bleeding and to thrombotic events. A higher vWF antigen may be a consequence of endothelial damage in Eisenmenger syndrome, but the cause for an increase of anti-ß2-glycoprotein is unknown.
Assuntos
Cardiopatias Congênitas/complicações , Adulto , Idoso , Feminino , Cardiopatias Congênitas/sangue , Humanos , Hipertensão Pulmonar/sangue , Masculino , Volume Plaquetário Médio , Pessoa de Meia-Idade , Agregação Plaquetária , Contagem de PlaquetasRESUMO
Double ductus arteriosus with anomalous origin of the right pulmonary artery is a rare congenital heart disease. Echocardiography is the first-choice method to diagnose pulmonary arteries and presence of the arterial ductus. Computed tomography (CT) angiography confirms the final diagnosis of the anomalous origin of the pulmonary artery. We report a case diagnosed using 40-slice CT angiography where this case demonstrated presence of both ducts and an anomalous origin of right pulmonary artery from the right-sided ductus arteriosus.
Assuntos
Anomalias dos Vasos Coronários/diagnóstico por imagem , Seio Aórtico/diagnóstico por imagem , Fístula Vascular/diagnóstico por imagem , Angiografia Coronária , Anomalias dos Vasos Coronários/cirurgia , Ecocardiografia , Feminino , Humanos , Recém-Nascido , Seio Aórtico/anormalidades , Seio Aórtico/cirurgia , Ultrassonografia Pré-Natal , Fístula Vascular/congênito , Fístula Vascular/cirurgiaRESUMO
No disponible